National Research (NASDAQ:NRC) Posts Quarterly Earnings Results, Beats Estimates By $0.46 EPS

Posted by Brenda Bartman on Jul 28th, 2026

National Research (NASDAQ:NRC – Get Free Report) issued its earnings results on Tuesday. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.46, Zacks reports. National Research had a net margin of 6.52% and a return on equity of 122.73%.

National Research Stock Up 4.9%

Shares of NRC stock traded up $1.04 during mid-day trading on Tuesday, reaching $22.31. 77,542 shares of the company’s stock traded hands, compared to its average volume of 108,681. National Research has a 12 month low of $11.01 and a 12 month high of $23.25. The company has a market cap of $507.42 million, a P/E ratio of 57.20 and a beta of 0.35. The company’s 50-day moving average price is $20.38 and its 200-day moving average price is $18.31. The company has a quick ratio of 0.52, a current ratio of 0.52 and a debt-to-equity ratio of 5.48.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Weiss Ratings raised shares of National Research from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Citizens Jmp assumed coverage on National Research in a research note on Monday, June 22nd. They issued a “market outperform” rating and a $23.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

View Our Latest Stock Analysis on NRC

Hedge Funds Weigh In On National Research

Several large investors have recently modified their holdings of NRC. Two Sigma Investments LP boosted its stake in National Research by 99.0% during the 3rd quarter. Two Sigma Investments LP now owns 60,912 shares of the company’s stock valued at $778,000 after purchasing an additional 30,296 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of National Research by 394.2% during the 1st quarter. Jane Street Group LLC now owns 52,411 shares of the company’s stock valued at $671,000 after buying an additional 41,806 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in National Research by 180.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 49,076 shares of the company’s stock worth $627,000 after buying an additional 31,599 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in National Research by 11.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 25,124 shares of the company’s stock worth $472,000 after purchasing an additional 2,526 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of National Research by 14.9% in the fourth quarter. Invesco Ltd. now owns 21,598 shares of the company’s stock worth $405,000 after buying an additional 2,799 shares in the last quarter. Hedge funds and other institutional investors own 47.26% of the company’s stock.

National Research Company Profile

(Get Free Report)

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.